 The FDA has approved a second indication for GlaxoSmithKline plcs NYSE: GSK Jemperli dostarlimab-gxly. The approval comes for adult patients with mismatch repair deficient dMMR recurrent or advanced solid tumors that have progressed on or following prior treatment and have no satisfactory alternative treatment options. 